<DOC>
	<DOCNO>NCT02249117</DOCNO>
	<brief_summary>Study compare pharmacokinetic pharmacodynamic effect escalate dosage recombinant human pyro-Glu MCP-1 ( BIWH 3 ) Duffy positive vs. Duffy negative healthy male volunteer : plasma level monocyte chemotactic protein-1 ( MCP-1 ) marker leukocyte , coagulation , platelet endothelial activation quantify ; To examine safety BIWH 3 setting</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics BIWH 3 Healthy Duffy Positive vs. Duffy Negative Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subject determine result screen Erythrocyte Fy positive negative individual expression Duffy ( Fy ) receptor may influence MCP1 plasma level human Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Age ≥ 18 ≤ 50 year Body mass index : ≥18 kg/m2 &lt; 30 kg/m2 Normal finding medical history physical examination unless investigator considers abnormality clinically irrelevant Normal laboratory variable unless investigator considers abnormality clinically irrelevant Normal pharmacodynamic variable determine baseline visit Normal response glucose tolerance test Any find medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Current history : gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , autoimmune , hormonal disorder , diseases central nervous system ( epilepsy ) , psychiatric disorder cancer Symptoms clinically relevant illness 3 week prior plan administration study drug History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy / hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Any Electrocardiogram ( ECG ) value outside reference range clinical relevance include , limited QRS interval &gt; 110 m QTcB &gt; 450 m Intake drug long halflife ( &gt; 24 hour ) within 1 month prior plan administration study drug Use drug might influence result trial within 10 day prior plan administration trial Participation another trial investigational drug within 2 month prior plan administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day Current history drug , alcohol , tobacco caffeine abuse Blood donation within 1 month prior plan administration trial Excessive physical activity within 5 day prior plan administration study drug trial Seropositivity hepatitis B antigen ( HBsAg ) , hepatitis C ( HCV ) , HIV 1 , HIV 2 antibody Weight 95 kg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>